News

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...
Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...
In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...
Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...
Rep. Madeleine Dean's Banana Burn Against Commerce Secretary Howard Lutnick Goes Viral ...
Ovarian cancer isn't silent - learn the early warning signs. Persistent bloating, pelvic pain, urinary symptoms revealed.
Michele Hoaglund, who bought the store about a decade ago from its founding owners, was diagnosed with ovarian cancer around ...
US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...
Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.
Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.
Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.